Cardinale et al. [22] first reported that long-term treatment with the pan-HDAC inhibitor valproic acid (VPA) reduces cardiac hypertrophy, inflammation, and hypertensive responses in spontaneously hypertensive rats (SHR). Here, HDAC9 is linked to cardiac hypertrophy.